Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0Cancer Biology & Therapy

RBBP5 drives cancer stem cell-like characteristics by suppressing the hippo signaling pathway through WNT5A downregulation in breast cancer

  1. 1Department of HY-KIST Bio-convergence, College of Medicine, Hanyang University, Seoul, Republic of Korea
  2. 2Department of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea

Abstract

Background: Cancer stem cells (CSCs) are a major contributor to breast cancer recurrence and therapeutic resistance. This study investigates the oncogenic role of Retinoblastoma Binding Protein 5 (RBBP5) in driving CSC-like properties in breast cancer.

Methods: Genetic alterations in RBBP5 and their correlation with patient survival were analyzed using multiple breast cancer cohorts, including METABRIC, TCGA, and Kaplan-Meier (KM) plotter datasets. The impact of RBBP5 on CSC-like traits was assessed through tumorsphere formation and ALDEFLUOR assays, and in vivo xenograft models. To elucidate the underlying molecular mechanism, RNA sequencing (RNA-seq) was performed.

Results: Elevated RBBP5 expression was significantly associated with poor prognosis in breast cancer. (METABRIC: OS, p = 0.007; DFS, p = 0.049; TCGA: OS, p < 0.001; KM plotter: RFS, p < 0.001). RBBP5 overexpression enhanced tumorsphere-forming capacity, CSC-like population and tumor-initiating cell frequency. RNA-seq results revealed an enrichment of gene sets associated with negative regulation of cell growth, invasiveness, and stem cell population in RBBP5-knockdown cells. RBBP5 knockdown upregulated WNT5A, a non-canonical Wnt ligand, leading to Hippo pathway activation and subsequent suppression of YAP signaling. Pharmacological inhibition of YAP1 abrogated RBBP5-induced CSC-like properties, while suppression of MST1/2 in RBBP5-knockdown cells restored YAP activity and CSC traits.

Conclusions: These findings indicate that RBBP5 promotes CSC-like properties in breast cancer by repressing WNT5A-mediated Hippo signaling. We suggest RBBP5 as a potential biomarker for poor prognosis and propose that targeting YAP or activating the Hippo pathway could represent a promising therapeutic approach for patients with RBBP5-overexpressing tumors.

Related

  1. MYH9 confers doxorubicin resistance by stabilizing GRP78 and suppressing the PERK signaling-driven apoptotic pathway in breast cancer
    Jing Jiang, Tianzi You, Ziyi Zhao +3
    Frontiers in oncologyPeer-reviewedCC BYFull textCell biologyEurope PMCCrossref
  2. Sarcandra glabra alleviates intestinal injury via modulating gut microbiota and suppressing the IL-6/SOCS3 signaling pathway
    Shaowei Huang, Xiaomei Chi, Siting Song +6
    npj Science of FoodPeer-reviewedCC BYFull text1 citedGenetics & genomicsDOAJ
  3. The resveratrol monomer enhances resistance to bacterial pathogen through the activation of SA-NPR1 signaling pathway in Arabidopsis
    Yuqiao Ma, Sun Ho Kim, Minh Le Anh Pham +5
    Frontiers in plant sciencePeer-reviewedCC BYFull textPlant biologyEurope PMC
  4. Cardiac Extracellular Matrix derived from younger animals stabilizes macrophage inflammatory polarization through modulation of the interferon signaling pathway
    K. Nugnes, G. Costello, N. McCarey +2
    bioRxivPreprintCC BY-NC-NDFull textCell biologybioRxiv
  5. ADAM8 is associated with asthma exacerbation by promoting lung macrophages apoptosis resistance through PI3K/AKT signaling pathway
    Long Chen, Xinyu Wu, Huijun Liu +6
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
BibTeX
@article{moon2026rbbp5,
  title = {{RBBP5 drives cancer stem cell-like characteristics by suppressing the hippo signaling pathway through WNT5A downregulation in breast cancer}},
  author = {So-Jeong Moon and Young-Hyeon Kye and Gu Kong},
  journal = {Cancer Biology \& Therapy},
  year = {2026},
  month = nov,
  doi = {10.1080/15384047.2026.2756150},
  url = {https://doi.org/10.1080/15384047.2026.2756150},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - RBBP5 drives cancer stem cell-like characteristics by suppressing the hippo signaling pathway through WNT5A downregulation in breast cancer
AU  - So-Jeong Moon
AU  - Young-Hyeon Kye
AU  - Gu Kong
PY  - 2026
DA  - 2026/11/07
JO  - Cancer Biology & Therapy
DO  - 10.1080/15384047.2026.2756150
UR  - https://doi.org/10.1080/15384047.2026.2756150
AB  - Background: Cancer stem cells (CSCs) are a major contributor to breast cancer recurrence and therapeutic resistance. This study investigates the oncogenic role of Retinoblastoma Binding Protein 5 (RBBP5) in driving CSC-like properties in breast cancer.  Methods: Genetic alterations in RBBP5 and their correlation with patient survival were analyzed using multiple breast cancer cohorts, including METABRIC, TCGA, and Kaplan-Meier (KM) plotter datasets. The impact of RBBP5 on CSC-like traits was assessed through tumorsphere formation and ALDEFLUOR assays, and in vivo xenograft models. To elucidate the underlying molecular mechanism, RNA sequencing (RNA-seq) was performed.  Results: Elevated RBBP5 expression was significantly associated with poor prognosis in breast cancer. (METABRIC: OS, p = 0.007; DFS, p = 0.049; TCGA: OS, p < 0.001; KM plotter: RFS, p < 0.001). RBBP5 overexpression enhanced tumorsphere-forming capacity, CSC-like population and tumor-initiating cell frequency. RNA-seq results revealed an enrichment of gene sets associated with negative regulation of cell growth, invasiveness, and stem cell population in RBBP5-knockdown cells. RBBP5 knockdown upregulated WNT5A, a non-canonical Wnt ligand, leading to Hippo pathway activation and subsequent suppression of YAP signaling. Pharmacological inhibition of YAP1 abrogated RBBP5-induced CSC-like properties, while suppression of MST1/2 in RBBP5-knockdown cells restored YAP activity and CSC traits.  Conclusions: These findings indicate that RBBP5 promotes CSC-like properties in breast cancer by repressing WNT5A-mediated Hippo signaling. We suggest RBBP5 as a potential biomarker for poor prognosis and propose that targeting YAP or activating the Hippo pathway could represent a promising therapeutic approach for patients with RBBP5-overexpressing tumors.
SN  - 1538-4047
SN  - 1555-8576
ER  -